Optical system detects angiogenesis in breast cancers
An investigational device shown as a work-in-progress at the RSNA meeting promises to improve the detection of breast cancer by keying off the process of angiogenesis, which can transform an innocuous tumor into a lethal one by triggering the growth of new blood vessels to feed the cancer.
An investigational device shown as a work-in-progress at the RSNA meeting promises to improve the detection of breast cancer by keying off the process of angiogenesis, which can transform an innocuous tumor into a lethal one by triggering the growth of new blood vessels to feed the cancer.
The ComfortScan system being developed by Dobi Medical International uses optical technology to detect abnormal blood vessel proliferation. By producing images related to the physiology of abnormal vascularization, the device offers diagnostic information that cannot be generated by anatomically based breast imaging technologies such as mammography and ultrasound.
Unlike x-ray mammography equipment, ComfortScan does not rely on the delivery of ionizing radiation to generate images of the breast. It uses light-emitting diodes to register blood vessels.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
Emerging AI Mammography Model May Enhance Clarity for Initial BI-RADS 3 and 4 Classifications
May 21st 2025In a study involving over 12,000 Asian women, researchers found that an artificial intelligence (AI) model converted over 83 percent of false positives in patients with initial BI-RADS 3 and 4 assessments into benign BI-RADS categories.
